S299: ORELABRUTINIB, AN IRREVERSIBLE INHIBITOR OF BRUTON’S TYROSINE KINASE, FOR TREATMENT OF PRIMARY IMMUNE THROMBOCYTOPENIA: RESULTS OF A RANDOMIZED, OPEN-LABEL PHASE II STUDY

Authors: Yan Shi, Hu Zhou, Ruibin Huang, Fang Wang, Heng Mei, Lie Lin, Jingming Guo, Xin Zhou, Zhenyu LI, Yaorong Liu, Sichen LI, Wei Zhou, Ming Hou

Published: 2023-08-09

DOI: 10.1097/01.hs9.0000968108.98119.51

Source: Full article

---

Abstract

No abstract found.